Brain tumors in infants (defined as children younger. Resection of infantile brain tumors after neoadjuvant chemotherapy: the St.
|
|
- Madlyn McCoy
- 5 years ago
- Views:
Transcription
1 J Neurosurg Pediatrics 8: , 8: , 2011 Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience Clinical article Mark Van Poppel, M.D., 1 Paul Klimo Jr., M.D., M.P.H., 1 Mariko Dewire, M.D., 2 Robert A. Sanford, M.D., 1 Frederick Boop, M.D., 1 Alberto Broniscer, M.D., 2 Karen Wright, M.D., 2 and Amar J. Gajjar, M.D. 2 1 Division of Pediatric Neurosurgery, University of Tennessee College of Medicine; and 2 Department of Oncology, Division of Neurooncology, St. Jude Children s Research Hospital, Memphis, Tennessee Object. Brain tumors in infants are often large, high grade, and vascular, making complete resection difficult and placing children at risk for neurological complications and excessive blood loss. Neoadjuvant chemotherapy may reduce tumor vascularity and volume, which can facilitate resection. The authors evaluated how an ongoing institutional prospective chemotherapy trial would affect patients who did not have a gross-total resection (GTR) immediately and who therefore required further surgical intervention to achieve definitive tumor resection. Methods. Thirteen infants (4 girls and 9 boys) who were enrolled in an institutional protocol in which they were treated with multiagent chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide with vinblastine for high-risk patients) subsequently underwent second-look surgery. The primary outcome was extent of resection achieved in postchemotherapy surgery. Secondary outcomes included intraoperative blood loss, radiographic response to the chemotherapy, complications during chemotherapy, and survival. Results. Three infants underwent biopsy, 9 underwent subtotal resection, and 1 patient did not undergo surgery prior to chemotherapy. On subsequent second-look surgery, 11 of 13 patients had a GTR, 1 had a near-total resection, and 1 had a subtotal resection. In each case, a marked reduction in tumor vascularity was observed intraoperatively. The average blood loss was 19% of estimated blood volume, and 6 (46%) of 13 patients required a blood transfusion. Radiographically, chemotherapy induced a reduction in tumor volume in 9 (69%) of 13 patients. Emergency surgery was required in 2 patients during chemotherapy, 1 for intratumoral hemorrhage and 1 for worsening peritumoral edema. The average follow-up period for this cohort was 16.5 months, and at last follow-up, 4 patients (31%) had died, 1 patient had progressive metastatic spinal disease, and the rest had either no evidence of disease or stable disease. Conclusions. A GTR of pediatric brain tumors is one of the most important predictors of outcome. The application of the authors neoadjuvant induction chemotherapy protocol in a variety of tumor types resulted in devascularization of all tumors and volume regression in the majority, and subsequently facilitated resection, with acceptable intraoperative blood loss. Intracranial complications may occur during chemotherapy, ranging from incidental and asymptomatic to life threatening, necessitating close monitoring of these children. (DOI: / PEDS11158) Key Words neoadjuvant chemotherapy pediatric brain tumor infant blood loss surgery oncology Abbreviations used in this paper: ATRT = atypical teratoid/ rhabdoid tumor; CPC = choroid plexus carcinoma; EBL = estimated blood loss; GBM = glioblastoma multiforme; GTR = gross-total resection; HGG = high-grade glioma; NTR = near-total resection; PNET = primitive neuroectodermal tumor; STR = subtotal resection. J Neurosurg: Pediatrics / Volume 8 / September 2011 Brain tumors in infants (defined as children younger than 36 months of age) are rare, and they constitute a challenge from many perspectives. Tumors are often malignant, and radiation, a major component in the management of brain tumors in older children, is delayed or avoided if possible because of the well-known adverse late complications of this therapy, including growth impairment, endocrinopathies, neurocognitive decline, and secondary radiation-induced malignancies. 15 The therapeutic limitations of chemotherapy and irradiation render resection of infantile brain tumors highly essential when feasible. Maximal cytoreductive surgery is the goal with many infantile brain tumors because it has been shown to have a high correlation with improved outcomes. 6,12,15 However, this may not be possible if the tumor is large or hypervascular, because resection of such a tumor can result in the loss of an unacceptably high proportion of the total blood volume. In these patients, a combination of treatment regimens may provide the best opportunity for a successful outcome. 251
2 M. Van Poppel et al. In 2007, a prospective study was initiated at St. Jude Children s Research Hospital to evaluate the effectiveness of a chemotherapeutic regimen for children younger than 3 years of age in whom a brain tumor was diagnosed. The impetus for this protocol was to see whether this risk-stratified regimen would provide the same or better outcomes as prior chemotherapy regimens, but with less toxicity. The patients in the current report represent a subset of children enrolled in this trial in whom neoadjuvant chemotherapy was followed by surgery to resect the tumor. The chemotherapy is expected to reduce the tumor size sufficiently to allow definitive resection in these patients. We reviewed the surgical outcomes of infants with malignant brain tumors who had either no surgical intervention, a biopsy, or an STR followed by induction chemotherapy and then second-look surgery for definitive resection. Methods Study Design and Outcomes The St. Jude Hospital infant protocol, SJYC07, is a multiinstitutional, institutional review board approved study for children younger than 36 months of age with a CNS tumor. The protocol includes a risk-stratified approach. All patients receive similar induction chemotherapy that comprises high-dose methotrexate (5 g/m 2 ), cisplatin (75 mg/m 2 ), vincristine (1 mg/m 2 ), and cyclophosphamide (1.5 g/m 2 ), with vinblastine (1 mg/m 2 ) added for patients with high-risk disease (that is, those with metastatic disease at diagnosis). The patients reported in this series represent only those who either had no surgery or who did not have a GTR with their initial surgery, and who were thought to be candidates for additional surgery after their induction chemotherapy. Most of the initial surgeries were performed at other institutions. Secondlook or postchemotherapy surgery was performed after it was determined that the patient s response to the induction chemotherapy was maximized, usually during a weekly multidisciplinary brain tumor meeting. The indication to proceed with postchemotherapy surgery was either a regrowth of tumor after initial regression, no further reduction in tumor volume with repeated cycles of chemotherapy, or new emergency or urgent radiographic changes (for example, intratumoral hemorrhage). Typical descriptive statistics, such as patient age, sex, weight at the time of each surgery, estimated blood volume, use of initial surgery (biopsy or STR), and tumor type were collected. Perioperative data included the number of rounds of induction chemotherapy given, chemotherapyrelated systemic complications, and drugs administered. The primary outcome was the extent of resection performed after chemotherapy, categorized as GTR (no radiographically evident residual lesion on postoperative MR imaging); NTR (defined as < 1.5 cm 3 of residual tumor); or STR (defined as > 1.5 cm 3 of residual tumor). Secondary outcomes were intraoperative blood loss (both as an absolute volume and as a percentage of the child s estimated blood volume), the need for a blood transfusion at any time during the child s immediate postoperative hospital stay, radiographic response to chemotherapy, neurological complications during neoadjuvant chemotherapy, and survival. Results Patient Characteristics Between December 2007 and February 2011, almost 90 patients have been enrolled in the SJYC07 protocol. Of these, 13 patients underwent a postchemotherapy, secondlook surgery, and they make up the cohort in this report (Table 1). There were 9 boys and 4 girls, with an average age of 22.5 months (range 1 34 months). No child had metastatic craniospinal disease at the time of enrollment into the study. All patients except 1 underwent an initial surgery at an outside facility before enrollment in the protocol. Prechemotherapy surgery consisted of an STR in 9 patients and a biopsy in 3. One patient, a 1-month-old boy who had a large hemispheric tumor with imaging characteristics consistent with a high-grade neoplasm that was subsequently diagnosed as an HGG (GBM), received chemotherapy as the initial treatment (see Case 5 below) prior to any surgical intervention. The patients had various tumor types: ependymoma (5 patients); supratentorial PNET (3); ATRT (2); HGG (2); and CPC (1). All patients underwent at least 1 cycle of induction chemotherapy, as follows: 3 patients received 1 cycle; 3 underwent 2 cycles; 3 received 3 cycles; and 4 underwent 4 cycles of chemotherapy. Primary and Secondary Outcomes The average time between the initial prechemotherapy and postchemotherapy surgery was 14.9 weeks, with a range of 7 22 weeks. Eight surgeries were supratentorial, whereas 5 were infratentorial. A GTR was achieved in 11 (85%) of 13 patients, NTR in 1 patient, and STR in 1 patient (7.5% each). One of the patients who had a GTR achieved this with a planned, 2-stage operation. In all cases, even in the patient who required emergency resection because of intratumoral hemorrhage, the senior surgeons (F.B. and R.S.) noted a marked reduction in tumor vascularity and enhanced resectability. One patient required a repeat operation 3 days after a gross-total removal of a CPC for evacuation of a hematoma in his resection cavity (see Case 9 below). The average blood loss during the postchemotherapy surgery was 140 ml (range ml), and as a percentage of the patient s estimated preoperative blood volume, it averaged 19.4% (5.4% 79.4%). One outlier the same 1-month-old infant with a hemispheric HGG mentioned earlier lost 79.4% (250 ml) of his blood volume. Excluding this patient, the range of blood loss was 5.4% 28.2%, with an average of 13.3%. Six (46%) of 13 patients required a transfusion, either intra- or postoperatively, without any complications. Radiographically, 9 (69%) of 13 patients exhibited a decrease in the tumor size during induction chemotherapy. Of the 4 patients who did not exhibit a radiographic response to the chemotherapy, 3 had ependymomas, and the fourth was the infant with a hemispheric GBM. This 1-month-old infant was 2 weeks into his induction chemotherapy when he developed an intratumoral hemorrhage that required urgent surgery. Three patients (23%) developed radiographically evident changes that required surgical intervention sooner than anticipated, 2 of them on an emergency basis: intratumoral hemorrhage, malignant 252 J Neurosurg: Pediatrics / Volume 8 / September 2011
3 Brain tumor resection in infants after neoadjuvant chemotherapy TABLE 1: Summary of treatment and outcome in 13 infants who underwent second-look surgery after induction chemotherapy* Case No. Age at Dx (mos), Sex Dx Initial Op No. of Courses of Induction Chemo Time From Prechemo to Postchemo Op (days) Postchemo Op EBL (ml) EBL as % of Total Blood Vol Current Status, FU (mos) 1 34, M anaplastic ependymoma biopsy 1 49 GTR alive, NED, , F ATRT biopsy GTR dead, , F ependymoma STR GTR alive, SD, , F HGG biopsy 1 55 NTR alive, SD, , M HGG NA 1 NA GTR alive, NED, , F spnet STR 2 87 GTR dead, , M ependymoma STR 4 54 GTR alive, SD, , M ependymoma STR STR alive, PMD, , M CPC STR 2 75 GTR alive, NED, , M ATRT STR GTR dead, , M spnet STR GTR alive, NED, , M ependymoma STR GTR alive, NED, , M spnet STR 2 94 GTR dead, 20.6 * Chemo = chemotherapy; FU = follow-up; NA = not applicable; NED = no evidence of disease; PMD = progressive metastatic disease; SD = stable disease; spnet = supratentorial PNET. peritumoral edema, and the development of an interhemispheric cyst with mass effect. Three other patients had 4 notable radiographically confirmed changes during chemotherapy that were managed nonoperatively. These consisted of spontaneous thrombosis of the transverse sinus in 2 patients, a small hemorrhage within a chronic subdural collection, and marked cystic degeneration of a CPC. The average follow-up duration for the cohort was 16.5 months, calculated from the date at which pathological diagnosis was made until the last follow-up date or death (Table 1). Four patients (31%) have died of their disease. One patient recently underwent surgery for progressive metastatic spinal disease 14.5 months after his posterior fossa ependymoma was diagnosed. The other 8 patients have either no evidence of disease (5 patients) or stable local disease (3). Illustrative Cases Case 5 In this boy a large hemispheric tumor was diagnosed at 1 month of age as a result of a workup for macrocephaly. His imaging raised concerns about a malignant neoplasm, and he was enrolled in the SJYC07 protocol without prior biopsy or attempted resection (Fig. 1A). Two weeks into induction chemotherapy his neurological status declined, and a CT scan demonstrated an intratumoral hemorrhage (Fig. 1B). The child was severely pancytopenic because of his chemotherapy. An emergency frontotemporoparietal craniotomy was performed, with GTR. Pathological analysis of the tissue was consistent with GBM. The patient lost 250 ml of blood, which was 79% of his estimated total blood volume, and he required an intraoperative blood and platelet transfusion. The child recovered well from surgery and has finished all planned therapy. His scans show no evidence of disease recurrence (Fig. 1C). J Neurosurg: Pediatrics / Volume 8 / September 2011 Case 9 This 26-month-old boy presented with emesis and ataxic gait. Imaging revealed a large complex mass centered in the atrium of the right lateral ventricle (Fig. 2A). He underwent a limited STR at an outside institution and a CPC was diagnosed. This surgery had to be terminated because the child lost the equivalent of 2 blood volumes with a minimal resection. He was then referred to St. Jude Hospital for further evaluation and treatment. After 2 courses of induction chemotherapy, there was a significant reduction in the solid component of the tumor with marked cystic degeneration (Fig. 2B). Seventy-five days after the start of chemotherapy, repeat imaging showed some increase in both the solid and cystic components. The patient then underwent a craniotomy, and a GTR was achieved. He lost 300 ml, or 28%, of his estimated blood volume and received a blood transfusion intraoperatively. He required a repeat craniotomy on postoperative Day 3 for evacuation of a hematoma in the resection cavity. The patient is currently on maintenance chemotherapy and is doing well 13.1 months postoperatively without evidence of recurrent tumor (Fig. 2C). Discussion Our study evaluated the effectiveness of neoadjuvant chemotherapy in 13 infants with brain tumors of various types, with a focus on its effect on surgical intervention, specifically the ability to perform a safe and successful GTR, the amount of intraoperative blood loss, and the need for perioperative blood transfusion. Infants with brain tumors not only have a significantly worse survival overall than older children with similar tumors, but they are at risk for developing treatment-induced complications, the most worrisome being neurotoxicity and its long-term effects. 6,7 From a surgical standpoint, the ability to achieve a GTR is 253
4 M. Van Poppel et al. Fig. 1. Case 5. This 1-month-old boy received a diagnosis of a large, heterogeneous mass occupying almost his entire left hemisphere, as seen on the axial T2-weighted image (A). Soon after starting chemotherapy, he had a sudden clinical decline, and a CT scan revealed that a portion of the tumor had hemorrhaged (B), necessitating emergency surgery. After a GTR, the patient is disease free, as shown on the T1-weighted image with contrast enhancement (C), and remains on maintenance chemotherapy. limited by the tumor size, its location, and its vascularity. Infants often harbor large, vascular tumors, and their relatively small blood volume limits how much blood loss can be tolerated with attempted resection. Our experience with the use of chemotherapy consisting of methotrexate, cisplatin, vincristine, and cyclophosphamide with vinblastine for high-risk disease prior to attempted definitive resection in this series of infants has been favorable thus far. A GTR was achieved in 11 (85%) of our 13 patients. One patient had an NTR, and another patient, a 28-month-old boy with a posterior fossa ependymoma, had an STR. A GTR continues to be the goal because, as in older children, aggressive resection portends better infant survival in all the major tumor types: medulloblastomas, ependymomas, choroid plexus tumors, supratentorial PNETs, ATRTs, and HGGs. 15 The degree of tumor vascularity is often difficult to assess, but it can be predicted to some degree based on tumor type (for example, CPC) or the presence of intratumoral flow voids on the preoperative MR imaging studies. We used intraoperative blood loss, and more specifically, the amount of blood loss calculated as a percentage of the child s circulating blood volume, as a variable representative of tumor vascularity, assuming that most but certainly not all of the blood loss occurs during the resection of the tumor. The average EBL was 19%, with 1 patient having a blood loss of 79%, as previously discussed. This average blood loss compares favorably with a previous report on CPC resection after chemotherapy, in which the average EBL was 15%. 5 Nearly half of the patients in our cohort (6 of 13) required blood transfusion either intra- or postoperatively, but there were no adverse events related to the transfusions. Additionally, we evaluated whether there was a response to the chemotherapy, which was defined as a reduction in the solid component of a tumor as seen on MR imaging. Nine patients (69%) demonstrated a decrease in tumor volume during chemotherapy. Of the 4 nonresponders, 3 were patients with ependymomas and 1 was the child who suffered an intratumoral hemorrhage 2 weeks after chemotherapy was initiated. We observed that the patients with ependymomas had either no response or a mild response to chemotherapy, compared with the more robust results we saw with the malignant, more proliferative tumor types such as PNET or CPC. Nonetheless, all ependymomas were significantly devascularized intraoperatively. In summary, although our chemotherapy protocol resulted in varying degrees of tumor shrinkage due to what we believe is a direct oncolytic effect, it appeared to devascularize all of the tumors temporarily, which greatly facilitated our ability to resect them. The developing nervous system in infants is at risk Fig. 2. Case 9. This 24-month-old boy underwent an STR of a CPC prior to induction chemotherapy. A: Axial T2-weighted MR imaging study obtained before the patient underwent chemotherapy, showing postoperative changes in addition to the large heterogeneous mass occupying the region of the right atrium of the lateral ventricle. B: After chemotherapy, there was a substantial decrease in the tumor, with cystic changes. C: A T1-weighted, contrast-enhanced image showing no evidence of recurrent disease after surgery. 254 J Neurosurg: Pediatrics / Volume 8 / September 2011
5 Brain tumor resection in infants after neoadjuvant chemotherapy for permanent injury as a result of treatment-induced toxicities, with craniospinal radiation in particular being strongly associated with deleterious late effects. 5,9,17,24 This has led to the development of innovative chemotherapeutic regimens in the hopes of delaying, minimizing, or eliminating radiation therapy. 19 Alkylating and irreversible DNA cross-linking drugs, such as cyclophosphamide and cisplatin, have been the mainstay chemotherapeutic agents for these patients since the mid-1980s, but are associated with side effects such as oto- and nephrotoxicity. 7 A recent report found that a carboplatin-based regimen had a similar response and outcome profile compared with the cisplatin regimen, but with a more favorable toxicity profile, the primary toxicity being myelosuppression. 10 Rutkowski et al. 19 demonstrated that infants with desmoplastic medulloblastomas and no metastatic disease can be successfully treated with surgery and chemotherapy alone. Their chemotherapy regimen consisted of intravenous high-dose methotrexate and intrathecal methotrexate, but the latter can cause radiographic leukoencephalopathy and a decrease in IQ score. Surgery is an important part of the treatment armamentarium for infants with brain tumors, but it has its challenges, primarily because of the small circulating blood volume. As chemotherapy became the primary therapy for infants in the late 1980s, this led some to use it in a limited fashion preoperatively to facilitate surgical extirpation. In 1989, Sanford et al. 20 published their series of 6 children (3 of them infants) with various high- and low-grade tumor types who underwent preoperative chemotherapy followed by complete tumor resection as determined by postoperative CT scans. The observations made by the authors of this paper 20 years ago mirror our experience today: when the tumor responds to chemotherapy, a gliotic interface develops between tumor and normal cerebral tissue that facilitates surgical dissection. The subarachnoid space is preserved and the vascularity of the tumor is significantly reduced. Radiotherapy facilitates surgery by reducing the vascularity of brain tumors but the tissue reaction obliterates the subarachnoid spaces and obscures the margin between normal brain and tumor. 20 Shortly after that publication, the group at The Hospital for Sick Children in Toronto reported their experience with treating CPCs. 22 A report from the same group only a few years earlier had concluded that because of size, vascularity, and invasiveness, the outcome with this tumor was dismal. 13 In their subsequent report, however, 4 of 11 patients had been treated in a neoadjuvant chemotherapy program involving VP16, ifosfamide, and carboplatinum. Under this treatment protocol, there was a reduced tumor volume and vascularity, which allowed a safer and more complete resection. The authors concluded that it would seem that consistent gross total removal may be an initial step toward better overall management and prognosis in this tumor type. Since these early reports, multiple other small series and case reports have demonstrated a benefit to neoadjuvant chemotherapy in a variety of tumors such as PNETs, pleomorphic xanthoastrocytoma, low-grade gliomas and HGGs, medulloblastoma, and, of course, CPCs. 1 4,7,11,12,14,18,20,21,23 Despite these reports, preoperative chemotherapy is not generally J Neurosurg: Pediatrics / Volume 8 / September 2011 considered a common approach to pediatric brain tumors, with the possible exception of choroid plexus tumors. A recent report, again by the Toronto group, demonstrated that second-look surgery after neoadjuvant chemotherapy (ifosfamide, carboplatin, etoposide [ICE]) resulted in complete resection in 9 of 10 patients with CPC. 14 However, despite the avoidance of radiation in their patients, the majority of survivors still suffered neurocognitive impairment. Our experience treating patients with ependymoma, on the other hand, has been particularly favorable. Posterior fossa ependymomas are notoriously difficult to excise completely, and patients are at high risk of neurological injury because of the tumor s proximity and adherence to the brainstem or cranial nerves. Surgery is the most important prognostic factor for survival. 16 Neoadjuvant chemotherapy resulted in devascularization of these tumors and significantly improved our ability to resect them, despite having mild to no actual tumor shrinkage. This finding could significantly change the way neurosurgeons and oncologists view the utility of chemotherapy in the management of ependymomas. To our knowledge, only one other group has previously reported on the use of preoperative chemotherapy in patients with ependymoma. Foreman et al. 8 reported on 4 patients who received various chemotherapy regimens between the initial surgery and the subsequent secondlook surgery. Three patients had complete resection, and all of these patients were alive at the time of publication. The authors stated that use of chemotherapy may prevent tumor progression during the interval between the first and second surgery, allows the patient to recover from the initial surgery, and may result in the tumor being more circumscribed and amenable to resection. We observed a number of unfavorable radiographic changes during chemotherapy. Some of these complications are attributable to the chemotherapy, whereas others may be more related to the disease itself. Three patients required tumor resection sooner than expected as a result of radiographic complications, 2 of them on an emergency basis. The intratumoral hemorrhage in our opinion was due to the combination of a large malignant tumor with areas of necrosis precipitated by chemotherapy-induced thrombocytopenia, as detailed in Case 5. The patient with the worsening peritumoral edema was a 34-month-old boy with a large supratentorial anaplastic ependymoma. He completed 1 round of induction chemotherapy, and shortly thereafter had a precipitous neurological decline, with a CT scan demonstrating malignant peritumoral edema. The exacerbation of the edema could certainly be due to the oncolytic effects of the chemotherapy. The patient with the interhemispheric cyst was a 2-month-old girl with a hemispheric HGG who developed a loculated interhemispheric CSF collection, away from the site of her tumor. We did have 2 patients who developed spontaneous asymptomatic transverse sinus thrombosis during chemotherapy, in one of whom a prothrombotic disorder was subsequently diagnosed. The marked cystic degeneration of the CPC in the 26-monthold patient (Case 9) is also attributed to the chemotherapy. There were no nonneurological, systemic complications due to chemotherapy in our patient population. 255
6 M. Van Poppel et al. The major limitation of this study is the small number of patients. Still, it represents the largest collection of children treated with neoadjuvant chemotherapy who then went on to undergo second-look surgery. We focused on the impact that neoadjuvant chemotherapy had on surgery, but long-term outcomes, including survival as well as neurocognitive and functional outcomes, are needed. We hope that the results of this study will generate interest in the use of neoadjuvant chemotherapy at other pediatric cancer centers and ultimately lead to collaborative studies, which is the most productive way of evaluating treatments in a population with such a rare condition. Conclusions Neoadjuvant chemotherapy effectively devascularized all tumors and reduced the volume of most tumors in our population of infants with brain malignancies. This had the effect of greatly enhancing our ability to achieve a complete surgical extirpation. Our protocol seems to be effective in a variety of tumor types, but patients must be closely monitored with serial imaging because the impact of chemotherapy on tumor size reduction can be temporary. Several of our patients experienced deleterious intracranial changes during chemotherapy, some of which were thought to be directly due to the chemotherapy. Although the use of neoadjuvant chemotherapy has been sporadically published over the past 20 years, we hope that our experience will rejuvenate it as a viable treatment option for infants, and possibly for older children, with brain tumors. Disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author contributions to the study and manuscript preparation include the following. Conception and design: Sanford, Boop, Broniscer, Wright, Gajjar. Acquisition of data: Klimo, Van Poppel, Dewire. Analysis and interpretation of data: Klimo, Van Poppel, Dewire. Drafting the article: Klimo, Van Poppel. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Klimo. Study supervision: Sanford, Boop, Broniscer, Wright, Gajjar. Formulated related trial: Broniscer, Wright, Gajjar. Acknowledgment The authors thank Kristin Kraus for her assistance in preparing this manuscript. References 1. Allen J, Wisoff J, Helson L, Pearce J, Arenson E: Choroid plexus carcinoma responses to chemotherapy alone in newly diagnosed young children. J Neurooncol 12:69 74, Cartmill M, Hewitt M, Walker D, Lowe J, Jaspan T, Punt J: The use of chemotherapy to facilitate surgical resection in pleomorphic xanthoastrocytoma: experience in a single case. Childs Nerv Syst 17: , Chow E, Reardon DA, Shah AB, Jenkins JJ, Langston J, Heideman RL, et al: Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys 44: , Di Rocco C, Iannelli A, La Marca F, Tornesello A, Mastrangelo S, Riccardi R: Preoperative chemotherapy with carboplatin alone in high risk medulloblastoma. Childs Nerv Syst 11: , Duffner PK, Cohen ME: Long-term consequences of CNS treatment for childhood cancer, Part II: Clinical consequences. Pediatr Neurol 7: , Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, et al: The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1: , Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328: , Foreman NK, Love S, Gill SS, Coakham HB: Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. Neurosurgery 40: , Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, et al: Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 23: , Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, et al: Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 115: , Grill J, Lellouch-Tubiana A, Elouahdani S, Pierre-Kahn A, Zerah M, Renier D, et al: Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. J Neurosurg 103 (4 Suppl): , Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, et al: Supratentorial malignant gliomas in childhood: a single institution perspective. Cancer 80: , Humphreys RP, Nemoto S, Hendrick EB, Hoffman HJ: Childhood choroid plexus tumors. Concepts Pediatr Neurosurg 7: 1 18, Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, et al: Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. Clinical article. J Neurosurg Pediatr 5: , Lafay-Cousin L, Strother D: Current treatment approaches for infants with malignant central nervous system tumors. Oncologist 14: , Merchant TE: Three-dimensional conformal radiation therapy for ependymoma. Childs Nerv Syst 25: , Packer RJ, Gurney JG, Punyko JA, Donaldson SS, Inskip PD, Stovall M, et al: Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 21: , Razzaq AA, Cohen AR: Neoadjuvant chemotherapy for hypervascular malignant brain tumors of childhood. Pediatr Neurosurg 27: , Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth- Metz M, Soerensen N, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352: , Sanford RA, Horowitz ME, Kun LE, Jenkins JJ III, Simmons JCH, Kovnar EH: Preoperative chemotherapy to facilitate the total resection of pediatric brain tumors. Concepts Pediatr Neurosurg 9: , Souweidane MM, Johnson JH Jr, Lis E: Volumetric reduction of a choroid plexus carcinoma using preoperative chemotherapy. J Neurooncol 43: , St Clair SK, Humphreys RP, Pillay PK, Hoffman HJ, Blaser SI, Becker LE: Current management of choroid plexus carcinoma in children. Pediatr Neurosurg 17: , Valera ET, Serafini LN, Machado HR, Tone LG: Complete surgical resection in children with low-grade astrocytomas after neoadjuvant chemotherapy. Childs Nerv Syst 19:86 90, Walter AW, Mulhern RK, Gajjar A, Heideman RL, Reardon D, Sanford RA, et al: Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children s Research Hospital. J Clin Oncol 17: , 1999 Manuscript submitted April 20, Accepted June 7, Address correspondence to: Paul Klimo Jr., M.D., M.P.H., Semmes-Murphey Neurologic & Spine Clinic, 6325 Humphreys Boulevard, Memphis, Tennessee pklimo@semmesmurphey.com. 256 J Neurosurg: Pediatrics / Volume 8 / September 2011
Outcome and Prognostic Features in Pediatric Gliomas
Outcome and Prognostic Features in Pediatric Gliomas A Review of 6212 Cases From the Surveillance, Epidemiology, and End Results Database Ibrahim Qaddoumi, MD, MS 1 ; Iyad Sultan, MD 2 ; and Amar Gajjar,
Update on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
Pediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
Key Words. Infants Brain tumors Chemotherapy Radiation therapy
The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Pediatric Oncology Current
Radiation therapy is the most effective adjuvant therapy in children
CLINICAL REPORT PEDIATRICS Imaging Changes in Very Young Children with Brain Tumors Treated with Proton Therapy and Chemotherapy N.D. Sabin, T.E. Merchant, J.H. Harreld, Z. Patay, P. Klimo, Jr, I. Qaddoumi,
CNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3
CNS pathology Third year medical students Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3 Pilocytic astrocytoma Relatively benign ( WHO grade 1) Occurs in children and young adults Mostly: in the cerebellum
Childhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients
ORIGINAL ARTICLE Brain Tumor Res Treat 2017;5(2):70-76 / pissn 2288-2405 / eissn 2288-2413 https://doi.org/10.14791/btrt.2017.5.2.70 Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective
Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
Small and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
Choroid plexus carcinoma: A case report
Choroid plexus carcinoma: A case report Primož Strojan 1, Mara Popović 2, Katarina Šurlan 3, Berta Jereb 1 1 Department of Radiotherapy, Institute of Oncology, 2 Institute of Pathology, Medical Faculty
BRAIN TUMORS IN INFANTS
BRAIN TUMORS IN INFANTS Dr Sergio Valenzuela M.D-( ISPN-ESPN-FLANC)&cols. Head Pediatric Neurosurgery Unit I Instituto de NeurocirugiaAsenjo Santiago CHILE RATE OF MENINGEAL,BRAIN AND OTHER CNS MALIGNANT
Radiation therapy is the most effective adjuvant therapy in
Published July 19, 2012 as 10.3174/ajnr.A3219 CLINICAL REPORT N.D. Sabin T.E. Merchant J.H. Harreld Z. Patay P. Klimo, Jr I. Qaddoumi G.T. Armstrong K. Wright J. Gray D.J. Indelicato A. Gajjar Imaging
Case Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child
Case Reports in Oncological Medicine Volume 2013, Article ID 815923, 4 pages http://dx.doi.org/10.1155/2013/815923 Case Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child Y. T.
Medulloblastoma is the most common malignant brain
CLINICAL AND LABORATORY OBSERVATIONS Chronic Residual Lesions in Metastatic Medulloblastoma Patients Iris Fried, MD,*w Annie Huang, MD, PhD,* Ute Bartels, MD,* Uri Tabori, MD,* Normand Laperriere, MD,z
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: Original Effective Date: MM.07.013 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 02/24/2012
The therapy of infantile malignant brain tumors: current status?
Journal of Neuro-Oncology (2005) 75: 279 285 Ó Springer 2005 DOI 10.1007/s11060-005-6752-x Childhood Brain Tumors The therapy of infantile malignant brain tumors: current status? Chantal Kalifa and Jacques
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
CNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
High-dose Chemotherapy With Autologous Stem Cell Rescue for Children With Recurrent Malignant Brain Tumors
1345 High-dose Chemotherapy With Autologous Stem Cell Rescue for Children With Recurrent Malignant Brain Tumors Chie-Schin Shih, MD 1 Gregory A. Hale, MD 2 Lindsey Gronewold, MSc 1 Xin Tong, MPH 1,3 Fred
Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
Prior to 1993, the only data available in the medical
Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
available at journal homepage:
E U R O P E A N J O U R NA L O F CA N C E R46 (21) 12 133 available at www.sciencedirect.com journal homepage: www.ejconline.com Primary postoperative chemotherapy without radiotherapy for treatment of
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas
Neurosurg Focus 4 (4):Article 3, 1998 Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas Albert Moghrabi, M.D., Henry S. Friedman, M.D., David M. Ashley, M.B.B.S., Ph.D., Krystal S.
CHAPTER 11 Tumors Originating in the Brain Medulloblastomas, PNETs and Ependymomas
Tumors Originating in the Brain Medulloblastomas, PNETs and Ependymomas Foolishly, I waited 7 months before I joined this (or any) group. By that time, my son had radiation, chemo, and a recurrence of
Tandem high-dose chemotherapy and auto-sct for malignant brain tumors in children under 3 years of age
Bone Marrow Transplantation (2013) 48, 932 938 & 2013 Macmillan Publishers Limited All rights reserved 0268-3369/13 www.nature.com/bmt ORIGINAL AICLE Tandem high-dose chemotherapy and auto-sct for malignant
Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
Intrinsic brainstem tumors may be a challenge to the
J Neurosurg Pediatrics 14:598 603, 2014 AANS, 2014 Neurosurgical treatment of pediatric low-grade midbrain tumors: a single consecutive institutional series of 15 patients Clinical article Tryggve Lundar,
Protocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
Collection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
Epidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore
314 Original Article Epidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore Mei-Yoke Chan, 1 MBBS, MMed (Paeds), MRCP (UK), Wan-Yee Teo, 2 MBBS, Wan-Tew Seow, 3 MBBS, FRACS (Neurosurg),
PROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
General: Brain tumors are lesions that have mass effect distorting the normal tissue and often result in increased intracranial pressure.
1 Lecture Objectives Know the histologic features of the most common tumors of the CNS. Know the differences in behavior of the different tumor types. Be aware of the treatment modalities in the various
Astroblastoma: Radiologic-Pathologic Correlation and Distinction from Ependymoma
AJNR Am J Neuroradiol 23:243 247, February 2002 Case Report Astroblastoma: Radiologic-Pathologic Correlation and Distinction from Ependymoma John D. Port, Daniel J. Brat, Peter C. Burger, and Martin G.
Case 1. Maysa Al-Hussaini MD FRCPath
Case 1 Maysa Al-Hussaini MD FRCPath MAYSA King AL-HUSSAINI Hussein Cancer MD Center MRCPATH KING HUSSEIN Amman CANCER Jordan CENTER Clinical history 4 year old boy History of frontal headache, sleepiness.
Department of Neurosurgery, Great Ormond Street Hospital, London, United Kingdom
CLINICAL ARTICLE J Neurosurg Pediatr 21:563 573, 2018 Surgical decision-making in the management of childhood tumors of the CNS disseminated at presentation Matthew A. Kirkman, MEd, MRCS, Richard Hayward,
7/1/2015. Radiotherapy in Infant Brain Tumors. Goals and Objectives. Primary Brain and CNS Tumors (0-14 years) Brain Tumors (1 to 4 years)
Radiotherapy in Infant Brain Tumors ARNOLD C. PAULINO, M.D. PROFESSOR OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER AND TEXAS CHILDREN S HOSPITAL Radiotherapy in Infant Brain Tumors 1. Try to Avoid Irradiation
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: 8.01.28 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas
Treatment of Recurrent. Central Nervous System. Primitive Neuroectodermal Tumours (PNETs) in Children and Young People. Version 1.
Treatment of Recurrent Central Nervous System Primitive Neuroectodermal Tumours (PNETs) in Children and Young People Version 1.0 September 2011 Barry Pizer on behalf of the CCLG CNS Interest Group Guidance
Carol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
Pediatric Brain Tumors Pre, Intra & Post Op Evaluation and Management. Timothy M. George, MD, FACS, FAAP
Pediatric Brain Tumors Pre, Intra & Post Op Evaluation and Management Timothy M. George, MD, FACS, FAAP PEDIATRIC BRAIN TUMORS BACKGROUND: Incidence: Third most common pediatric tumor type (leukemia, neuroblastoma,
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment. Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania May 13, 2016 Disclosures None to declare 2 Outline Epidemiology
Case Report Intracranial Capillary Hemangioma in the Posterior Fossa of an Adult Male
Case Reports in Radiology Volume 2016, Article ID 6434623, 4 pages http://dx.doi.org/10.1155/2016/6434623 Case Report Intracranial Capillary Hemangioma in the Posterior Fossa of an Adult Male Jordan Nepute,
Supra- and infratentorial brain tumors from childhood to maternity
Supra- and infratentorial brain tumors from childhood to maternity What to expect? I am going to show you the characteristic imaging findings of following tumors: Thierry A.G.M. Huisman, MD, FICIS, EQNR
Medulloblastoma in childhood: results of radical resection and low-dose neuraxis radiation therapy
J Neurosurg 64:238-242, 1986 Medulloblastoma in childhood: results of radical resection and low-dose neuraxis radiation therapy TADANOR! TOMITA, M.D., AND DAVID G. MCLONE, M.D., PH.D. Division of Pediatric
GLIOMA - VENOUS THROMBOEMBOLISM. Miguel Navarro. Hospital Universitario de Salamanca-IBSAL
GLIOMA - VENOUS THROMBOEMBOLISM Miguel Navarro. Hospital Universitario de Salamanca-IBSAL GLIOMA - VTE GLIOMA - VTE The two string problem Substantial risk for developing VTE Concern antithrombotic agents
Improved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies
Improved Survival after Gross Total Resection of Malignant Gliomas in Pediatric Patients from the HIT-GBM Studies CHRISTOF M. KRAMM 1, SABINE WAGNER 2, STEFAN VAN GOOL 3, HANSJÖRG SCHMID 4, RONALD STRÄTER
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
Citation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
Brain tumors: tumor types
Brain tumors: tumor types Tumor types There are more than 120 types of brain tumors. Today, most medical institutions use the World Health Organization (WHO) classification system to identify brain tumors.
Multicompartmental congenital intracranial immature teratoma
Neurology Asia 2013; 18(1) : 117 121 Multicompartmental congenital intracranial immature teratoma 1 Dharmendra Ganesan MS FRCS(SN), 1 Sheau Fung Sia MS MRCS, 1 Vairavan Narayanan MS, 2 Gnana Kumar FRCR,
SCIENTIFIC PROGRAMME SNOLA UPDATE ON NEURO- ONCOLOGY th March
SCIENTIFIC PROGRAMME SNOLA UPDATE ON NEURO- ONCOLOGY 2016 24th March 13h 13h45 pathology case case parasellar meningeoma case : posterior fossa pediatric tumor 13h45 16h Imaging for CNS lymphomas Parasellar
Case 7391 Intraventricular Lesion
Case 7391 Intraventricular Lesion Bastos Lima P1, Marques C1, Cabrita F2, Barbosa M2, Rebelo O3, Rio F1. 1Neuroradiology, 2Neurosurgery, 3Neuropathology, Coimbra University Hospitals, Portugal. University
SURGICAL MANAGEMENT OF BRAIN TUMORS
SURGICAL MANAGEMENT OF BRAIN TUMORS LIGIA TATARANU, MD, Ph D NEUROSURGICAL CLINIC, BAGDASAR ARSENI CLINICAL HOSPITAL BUCHAREST, ROMANIA SURGICAL INDICATIONS CONFIRMING HISTOLOGIC DIAGNOSIS REDUCING TUMOR
Case Report Tackling a Recurrent Pinealoblastoma
Case Reports in Oncological Medicine, Article ID 135435, 4 pages http://dx.doi.org/10.1155/2014/135435 Case Report Tackling a Recurrent Pinealoblastoma Siddanna Palled, 1 Sruthi Kalavagunta, 1 Jaipal Beerappa
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
Medulloblastoma: Conventional Radiation Therapy in Comparison to Chemo Radiation Therapy in The Post-operative Treatment of High-Risk Patients
Journal of the Egyptian Nat. Cancer Inst., Vol. 17, No. 4, December: 301-307, 2005 Medulloblastoma: Conventional Radiation Therapy in Comparison to Chemo Radiation Therapy in The Post-operative Treatment
Protocol Abstract and Schema
Protocol Abstract and Schema A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
Financial Disclosures I have no financial interests to disclose. Templar Eye Foundation Oppenheimer Family Foundation
Financial Disclosures I have no financial interests to disclose. Templar Eye Foundation Oppenheimer Family Foundation 2 Case 7 year old girl Initially parents noticed photophobia Then started to complain
Chemotherapy for Progressive Low- Grade Gliomas in Children Older than Ten Years: The Dana-Farber Experience
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/10578850 Chemotherapy for Progressive Low- Grade Gliomas in Children Older than Ten Years:
HHS Public Access Author manuscript J Neurosurg Pediatr. Author manuscript; available in PMC 2016 October 01.
The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience Eric Bouffet, MD 1, Jeffrey C. Allen, MD 2, James M. Boyett, PhD 3, Allen Yates, MD 4, Floyd Gilles,
Brain Tumors in Children
Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma
LOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
The difficulty of classifying pediatric high-grade gliomas
clinical article J Neurosurg Pediatr 17:453 459, 2016 The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience Eric Bouffet, MD, 1 Jeffrey C. Allen, MD,
Disclosures. Neurological Manifestations of Von Hippel Lindau Syndrome. Objectives. Overview. None No conflicts of interest
Neurological Manifestations of Von Hippel Lindau Syndrome ARNOLD B. ETAME MD, PhD NEURO-ONCOLOGY/NEUROSURGERY Moffitt Cancer Center Disclosures None No conflicts of interest VHL Alliance Annual Family
Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis
Tumors of the Central Nervous System
Tumors of the Central Nervous System 1 Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Introduction General: Brain tumors are lesions that have mass effect
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: Original Effective Date: MM.07.013 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/22/2016
CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
for brain tumours occurring in very young
Archives ofdisease in Childhood 1996; 74: 219-223 An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children 219 Linda S Lashford, Richard H A Campbell, H Rao Gattamaneni,
BRAIN TUMORS, which are composed of histologically
Long-Term Neurologic and Neurosensory Sequelae in Adult Survivors of a Childhood Brain Tumor: Childhood Cancer Survivor Study By Roger J. Packer, James G. Gurney, Judy A. Punyko, Sarah S. Donaldson, Peter
Imaging Findings of CNS Atypical Teratoid/Rhabdoid Tumors
AJNR Am J Neuroradiol 25:476 480, March 2004 Case Report Imaging Findings of CNS Atypical Teratoid/Rhabdoid Tumors Atilla Arslanoglu, Nafi Aygun, Deapak Tekhtani, Leslie Aronson, Ken Cohen, Peter C. Burger,
SYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS
SYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS María E. Echevarría, MD Assistant Professor University of Puerto Rico Medical Sciences Campus DISCLOSURES No disclosures INTRODUCTION Pediatric CNS
Neonatal Brain Tumors: A Review. Shaam Bodeliwala, Vikas Kumar, Daljit Singh*
Journal of Neonatal Surgery 2017; 6:30 Doi:10.21699/jns.v6i2.579 REVIEW ARTICLE Neonatal Brain Tumors: A Review Shaam Bodeliwala, Vikas Kumar, Daljit Singh* Department of Neurosurgery, G. B. Pant Institute
Theodore S. Johnson, MD, PhD
Front-line Therapy of DIPG Using IDO Pathway Inhibitor Indoximod in Combination with Radiation and Chemotherapy American Association of Cancer Research (AACR) 2018 Theodore S. Johnson, MD, PhD Georgia
NEURORADIOLOGY DIL part 5
NEURORADIOLOGY DIL part 5 Masses and tumors K. Agyem MD, G. Hall MD, D. Palathinkal MD, Alexandre Menard March/April 2015 OVERVIEW Introduction to Neuroimaging - DIL part 1 Basic Brain Anatomy - DIL part
Guideline for platelet transfusion thresholds for pediatric hematology/oncology patients. Khoa Ung bướu - Huyết học
Guideline for platelet transfusion thresholds for pediatric hematology/oncology patients Khoa Ung bướu - Huyết học Reference Sources: C17 Council (Canada) Guideline release date: June, 2010; Literature
A Case of Nongerminomatous Germ Cell Tumor with Fulminant Course Concomitant Leptomeningeal Metastasis
CSE REPORT rain Tumor Res Treat 2016;4(1):21-25 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.1.21 Case of Nongerminomatous Germ Cell Tumor with Fulminant Course Concomitant
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
The technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
Approximately 5% of pediatric brain tumors arise
Neuro-Oncology 13(6):680 689, 2011. doi:10.1093/neuonc/nor045 NEURO-ONCOLOGY Thalamic high-grade gliomas in children: a distinct clinical subset? Christof M. Kramm, Sandra Butenhoff, Ulrike Rausche, Monika
Pediatric Spine Tumors (and other masses)
Pediatric Spine Tumors (and other masses) Francisco A Perez, MD, PhD Assistant Professor Neuroradiology and Pediatric Radiology Seattle Children s Hospital University of Washington, Seattle Commercial
PEDIATRIC ONCOLOGY. e19 ABSTRACT. Conclusions. Objective. Methods KEY WORDS 1. INTRODUCTION. Results
TEMOZOLOMIDE IN PEDIATRIC CNS TUMOURS PEDIATRIC ONCOLOGY The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium
Table 7: PBTC Protocols [ ] Protocol Title Strata Status Neuroimaging Objective/Test
Table 7: PBTC Protocols [001 009] Protocol Title Strata Status Neuroimaging Objective/Test PBTC-001 PBTC-002 PBTC-003 PBTC-004 PBTC-005 PBTC-006 PBTC-007 PBTC-009 A Pilot of Systemic and Intrathecal Chemotherapy
Neuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18
Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:
11/27/2017. Modern Treatment of Meningiomas. Disclosures. Modern is Better? No disclosures relevant to this presentation
Modern Treatment of Meningiomas Michael A. Vogelbaum MD, PhD Professor of Neurosurgery Cleveland Clinic Disclosures No disclosures relevant to this presentation IP and royalties related to drug and device
Adult intramedullary astrocytomas of the spinal cord
J Neurosurg 77:355-359, 1992 Adult intramedullary astrocytomas of the spinal cord FRED J. EPSTEIN, M.D., JEAN-PIERRE FARMER, M.D., F.R.C.S., AND DIANA FREED Division of Pediatric Neurosurgery, Department
3. BACKGROUND AND RATIONALE
CHILDHOOD CANCER SURVIVOR STUDY Revised Analysis Concept Proposal 10-17 October 12, 2011 1. STUDY TITLE: Growth Hormone Exposure as a risk factor for the development of Subsequent Central Nervous System
TABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
Radioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ )
1 di 10 27/06/2016 08.16 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
STUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Original Article STUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER Grishma P. Jobanputra Tutor, Department of Pathology, B.J. Medical College,
Case Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
Oncology Volume 2009, Article ID 247873, 4 pages doi:10.1155/2009/247873 Case Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature